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Abstract
Background: A discussion is ongoing whether displaced femoral neck fractures in elderly patients
should be treated with a non-cemented or a cemented hemiarthroplasty. A recent Cochrane
analysis stresses the importance of further research into the relative merits of these techniques.
We hypothesise that non-cemented hemiarthroplasty will result in at least the same technical-
functional outcome and complication rate, with a shorter operation time.
Methods and design: A randomised controlled multicentre trial will be performed.
The study population consists of 200 patients of 70 years and older. Patients with a displaced
femoral neck fracture will be allocated randomly to have a cemented or a non-cemented
hemiarthroplasty. Data will be collected preoperatively, immediately postoperatively, and 6 weeks,
3 months and 1 year postoperatively.
The main outcome measures of this study are technical-functional results of the hemiarthroplasty,
duration of surgery, complications, and mid-thigh pain. Secondary outcome measures are living
conditions at final follow up, self-reported health-related quality of life, and radiological evaluation
of the hemiarthroplasty.
Conclusion: A recent Cochrane analysis did not find arguments in favour of either non-cemented
or cemented hemiarthroplasty. The forthcoming trial will compare treatment for a displaced
femoral neck fracture by cemented versus non-cemented hemiarthroplasty. Our results will be
published as soon as they become available.
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Background
Patients with a hip fracture form a heterogeneous group
with a high mortality rate, frequently troubled with mul-
tiple and severe co-morbidities. They are usually frail and
elderly, with more than 30% aged ≥ 85 years. In European
series, hip fracture patients have a 30-day mortality of
>10%, and a 1-year mortality of 25–30%.[1] Despite the
advances in surgical and anaesthetic techniques during
the last 20 years there has been no decrease in mortality
after surgical repair of hip fractures. [1]
The discussion about cemented or non-cemented hemiar-
throplasty is similar to the discussion about cemented or
cementless prostheses in primary hip arthroplasty. With
respect to the latter, conflicting data are presented by the
Swedish and Norwegian arthroplasty registers. [2,3] The
general opinion is that cementless hip arthroplasties are
more suitable for younger patients owing to the quality of
their bone stock. In hemiarthroplasty for hip fracture sur-
gery there are insufficient data from randomised trials to
conclude on the superiority of either type of arthroplasty.
Some authors found patients with cemented stems to
have less pain and better mobility postoperatively than
those with an non-cemented press fit.[4] Mid-thigh pain
is frequently reported in primary cementless total hip
arthroplasties. However, the reported incidence varies tre-
mendously; D'Lima et al.[5] in a control-matched study
reported 34%~vs.~3%, while Grübl et al.[6] in a non-con-
trolled series reported only 3% for cementless primary
total hip arthroplasties.
In cemented hemiarthroplasties polymethylmethacrylate
bone cement is applied at the time of surgery, forming a
solid bond between the prosthesis and the femoral bone;
on the contrary, in cementless prosthesis the bonding
between prosthesis and femur is dependent upon bony
in-growth. Potential advantages of cementing are a less
post-operative mid thigh pain, as the prosthesis is firmly
fixed within the femur, and a reduced long-term revision
rate from loosening of the prosthesis. Major side effects of
cement are cardiac arrhythmias and cardio-respiratory
collapse, which occasionally occur on application. These
potentially fatal complications are caused either by embo-
lism from marrow contents forced into the circulation or
by a direct toxic effect of the cement. [7] Another major
disadvantage of a cemented prosthesis is that revision
arthroplasty will be more difficult.
The non-cemented hemiarthroplasty used in our study is
the DB-10 (Biomet, Warsaw, USA), a straight collared
stem designed to provide primary stability and to prevent
migration. The primary stability of the stem, which has a
narrow tip to guide the implant, is optimised by metaphy-
seal anchoring: intimate trabecular bone contact and opti-
mised load transfer to the dynamic bone through to the
posterolateral angle situated in the axis of the neck. Sec-
ondary stability (prevention of migration) is facilitated by
optimizing bone in-growth surface through full hydroxya-
patite coating on macro-structured titanium and grooves
on A/P sides.
The cemented hemiarthroplasty used in our study is the
Müller Straight Stem prosthesis (Zimmer, Warsaw, USA),
developed with the advice of Professor M.E. Müller. It has
now been in use reliably for many years; Ried et al. found
a 15-year survival of 94%. [8] The fluted structure of the
stem, with the two particularly marked longitudinal
grooves AP in the stem axis, enables good cement adhe-
sion. The small proximal collar serves to compress the
cement, prevents the stem from sinking into the cement,
and, together with the fine-blasted surface of the straight
stem, achieves a stable anchorage of the implant.
Both prostheses have a unipolar head.
Methods and design
Study design
A single blinded randomised clinical multicentre trial will
be conducted. Patients will be randomised to 2 groups of
100 in the operation theatre by a randomisation compu-
ter (IRIS®, SDS Medical, The Netherlands). The treatment
will be either a cemented hemiarthroplasty or a non-
cemented hemiarthroplasty. If complications occur dur-
ing the procedure, the surgeon can change the procedure
to ensure best medical practice.
We acknowledge the possibility that the patients might be
able to tell which prosthesis they have received due to see-
ing their X ray during the outpatient clinic visits.
All patients with a displaced femoral neck fracture who are
admitted to one of the participating hospitals and meet
the inclusion criteria are asked to join the study. In case of
(mental) incompetence of the patient his/her legal repre-
sentative is consulted to obtain informed consent.
The study design, procedures and informed consent are
approved by the Medical Ethical Committee of South
West Netherlands.
Trial number Netherlands Trial Registry NTR 1508, http:/
/www.trialregister.nl
Study population
The study will be conducted at the Orthopaedic Depart-
ments of the Reinier de Graaf Gasthuis Delft, Ziekenhuis
Rijnstate Alysis Zorggroep Arnhem, Canisius Wilhelmina
Ziekenhuis Nijmegen and Elisabeth Ziekenhuis Tilburg.
Authors PP and AV will be responsible for the data and
safety monitoring.BMC Musculoskeletal Disorders 2009, 10:56 http://www.biomedcentral.com/1471-2474/10/56
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Inclusion criteria: patients aged = 70 years, with a dis-
placed femoral neck fracture (Garden type III or IV) not
older than 7~days are included.
Exclusion criteria: patients with a pathological fracture, a
fracture older than 7 days or ASA-V classification are
excluded.
Accrual is planned in the period from August 2008 to
August 2009.
Intervention
Patients will be receive either a cemented hemiarthro-
plasty, type Müller Straight Stem (Zimmer, Warsaw USA),
or a non-cemented hemiarthroplasty, type DB-10
(Biomet, Warsaw USA). Every surgeon will use the same
surgical approach for all implants – either straight lateral
or posterolateral. The approach of choice is up to the sur-
geon's preference, as Parker's Cochrane analysis has
shown that insufficient evidence is available for superior-
ity of either approach. [9]
Anaesthesia, analgesia and postoperative physical therapy
will be standardized in both groups.
Study variables
Preoperatively, social demographic data, the ASA classifi-
cation, Groningen Activity Restriction Scale (GARS, from
which the Parker mobility score can be derived) and the
SF-12 are obtained from each patient. [10,12,13]
The main outcome measures of this study are the func-
tional results, complication rate and duration of surgery
of the hemiarthroplasty.
Primary outcome measures
￿ Duration of surgery is defined as skin-to-skin surgi-
cal time, measured in minutes.
￿ Complications, divided in major and minor compli-
cations, are recorded during the follow up period of 1
year. The complications are ranked in the modified
Elixhauser mode, as described by Parvizi.[11]
￿ Functional outcome is measured by the Timed-Up-
and-Go (TUG) score and the Groningen Activity
Restriction Scale (GARS). [10,14]
￿ Postoperative mid-thigh pain is defined as pain
explicit in the front and mid part of the femur, and
scored on a 4-point ordinal scale (non/mild/moder-
ate/severe).
Secondary outcome measures
Living conditions at final follow up are measured in per-
centage of pre-fracture situation.
￿ Self reported health-related quality of life is meas-
ured by the SF 12. [13]
￿ Standard radiological evaluation of hemiarthro-
plasty and cement positioning and adequate size of
the hemiarthroplasty measured on plain AP and axial
X-rays of the operated hip. Adequate AP positioning is
defined as less than 10 degrees varus or valgus. Ade-
quate axial positioning is defined as 0–15 degrees
anteversion.
Follow up
The primary follow up for each patient will be 1 year. The
first postoperative assessment will be in a clinical setting
as the patient is still in the hospital. Assessments at 6, 12
and 52 weeks postoperatively will be made in the outpa-
tient clinic, unless the patient is not able to visit the out-
patient clinic; in that case questionnaires are mailed to the
patient (possibly through contact with a relative) to
obtain as much data as possible.
Determination of sample size
(a) Duration of surgery
It is expected that a cemented hemiarthroplasty on aver-
age will take 12 min longer than a non-cemented hemiar-
throplasty. Taking into account an estimated standard
deviation of 12 min, a 1-year mortality of 25% and 10%
of patients being lost to follow up or providing insuffi-
cient data we need a minimum of 46 patients per group.
(b) Functional outcome
Only for patients who are admitted from their own homes
or assisted living facilities, functional outcome is meas-
ured by the Timed-Up-and-Go (TUG) score and the Gro-
ningen Activity Restriction Scale, and mid-thigh pain a
non-inferiority design is used. [10,14]
￿ TUG performed; Giving the fact that at discharge
with a cut-off point of over 30 seconds is significantly
associated with falls. Less than 24 seconds is consid-
ered good functioning and has hardly any chance to
fall. 42 seconds is considered poor functioning with a
considerable chance to fall. [14] About 30% of the
patients have a poor score at discharge. About 70% of
all patients are admitted from their own homes or
assisted living facilities. If non-inferiority is considered
for TUG, a worsening of score from 30 to 42 is consid-
ered clinically relevant, with a SD of 10 sec., giving 16
patients a group. Corrected for the percentage admit-
ted from home or assisted living facility (70%) and the
drop out of 35% gives 34 patients a group
￿ GARS: The GARS data for this group of patients are
insufficient to make valid calculations of statistical
power. While data for multiple sclerosis patients and
healthy older patients are available, there are none forBMC Musculoskeletal Disorders 2009, 10:56 http://www.biomedcentral.com/1471-2474/10/56
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patients with a hip fracture. An estimate is made based
on preliminary data from a prospective survey in
progress. As soon as sufficient data from this survey are
available a final power calculation for GARS will be
done.
￿ Mid thigh pain
Rather varying figures about mid-tight pain are
reported in literature. D'Lima [5] reported 40 vs.
3% whereas v/d Wal et al. [15] reported 20 vs. 12%
in non-tight proximal fit prosthesis. Therefore the
average values of these two studies are taken.
π1 = 30%, π 2 = 7.5%, π = (30%+7.5%)/2 =
18.75%
n1  = n2  ≥ 21* (0,1875*(1-0,1875))/(0,225)2  =
63.2.
If the 25% 1-year mortality combined with
expected 10% lost-to follow-up (or missing val-
ues) is taken into account this number is raised by
35%, then a total of 86 patients a group is needed.
[16]
(c) Complications
The complication rate in this patient category is rather
high, but heterogeneous. The rate of thrombo-embolic
complications may depend on the type of intervention
(cemented vs. non-cemented).
However, the incidence of deep vein thrombosis (DVT)
and pulmonary embolism (PE) is such that an unachiev-
able high number of patients is needed to acquire ade-
quate power.
In conclusion, the total number of patients per group a set
on 100, making a total of 200 patients is needed for this
study.
Statistical analysis
Primary outcome measures
The differences in operation time, mid-thigh pain, com-
plications and TUG test will be analyzed using a Student's
t-test, setting the level of significance at p < 0.05.
Secondary outcome measures
We will use the chi-squared test or Fisher's exact test for
the binary variables. In cases of paired binary data (out-
come variables) we will use the McNemar test and a
paired t-test for mean differences. In the case of a statisti-
cally significant association (p < 0.05), we will use a logis-
tic regression to model the probability/odds of an
outcome.
The variables obtained from the clinical evaluation will be
tabulated and analysed as mean, standard deviation, min-
imum and maximum values. All analyses will be per-
formed using SPSS software (SPSS Inc., Chicago, IL, USA).
Kaplan Meijer survival analysis will be done after final fol-
low up, using failure (reoperation) and mortality as end-
points.
Discussion
In the treatment of displaced femoral neck fractures with
hemiarthroplasty in elderly patients the use of bone
cement is a controversial topic. A cemented hemiarthro-
plasty has been used in the majority of cases in most coun-
tries, but the non-cemented prosthesis is gaining
popularity. Parker et al. [1] concluded that there is only
limited evidence from randomised studies that cementing
prosthesis in place may reduce the amount of post-opera-
tive pain and may lead to improved mobility. Further-
more no study has adequately addressed long-term
outcome measures concerning this topic.
Cementing has potential physiologically adverse side
effects. The major side effects cardiac arrhythmias and car-
dio-respiratory collapse, which occasionally occur upon
application; these potentially fatal complications are
caused either by embolism from marrow contents forced
into the circulation or by a direct toxic effect of the
cement. [7] Transesophageal echocardiography could be
used to monitor emboli during surgery, but logistics pre-
vent this in our centres, as most patients are operated out-
side regular working hours. Nevertheless, Pitto et al. [17]
have already shown severe embolic events and intraoper-
ative pulmonary impairment during fixation of the
cemented femoral component in total hip arthroplasty,
while fixation without cement clearly demonstrated a low
risk of embolism. Clark et al. [18] found a transient but
significant reduction in cardiac output and stroke volume
for those receiving cement.
In non-cemented prostheses, bone quality is of impor-
tance; this is generally poor in elderly patients. LaPorte et
al. [19] stated two relative contraindications for non-
cemented total hip prosthesis: interference with bone in-
growth and inability to achieve a congruent fit; both of
these preclude establishment of rigid initial stability.
The purpose of this study is to compare treatment for dis-
placed femoral neck fracture by cemented versus non-
cemented hemiarthroplasty. We hypothesise that, relative
to cemented hemiarthroplasty, non-cemented hemiar-
throplasty will result in at least the same technical-func-
tional outcome and complication rate, with a shorter
operation time. The results of this study will be presented
as soon as they become available.Publish with BioMed Central    and   every 
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